Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary

IntroductionThe optimal trial design for assessing novel therapies in paediatric IBD (PIBD) is a subject of intense ongoing global discussions and debate among the different stakeholders. However, there is a consensus that the current situation in which most medications used in children with IBD are...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2020-01, Vol.69 (1), p.32-41
Hauptverfasser:	Turner, Dan, Griffiths, Anne M, Wilson, David, Mould, Diane R, Baldassano, Robert N, Russell, Richard K, Dubinsky, Marla, Heyman, Melvin B, de Ridder, Lissy, Hyams, Jeffrey, Martin de Carpi, Javier, Conklin, Laurie, Faubion, William A, Koletzko, Sibylle, Bousvaros, Athos, Ruemmele, Frank M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Age Factors Antibiotics Biological products Biological Products - administration & dosage Biological Products - therapeutic use Child Children Clinical trials Clinical Trials as Topic - methods Clinical Trials as Topic - standards Design Dose-Response Relationship, Drug Drug Approval - methods Drug dosages FDA approval Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - therapeutic use Humans Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Intestine Labeling Patient Selection Patients Pediatrics Pharmaceutical industry Research Design Severity of Illness Index Teenagers Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!